The pharmacokinetics of azithromycin in human serum and tissues

Journal of Antimicrobial Chemotherapy

Volumn 25, Issue , 1990, Pages 73-82

  Foulds, G ^a   Shepard, R M ^a   Johnson, R B ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VOLUNTEER;

ADOLESCENT; ADULT; AZITHROMYCIN; BIOLOGICAL AVAILABILITY; ERYTHROMYCIN; HALF-LIFE; HUMAN; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGE; TISSUE DISTRIBUTION;

EID: 0025096817     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/25.suppl_A.73     Document Type: Article

References (31)

1. Allen, H. H., Khalil, M. W., Vachon, D. & Glasier, M. A. (1988). Spiramycin concentrations in female pelvic tissues, determined by HPLC: A preliminary report. Journal of Antimicrobial Chemotherapy 22, Suppl.B, 111–6.
2. Barry, A. L. & Jones, R. N. (1988). Interpretative criteria for the agar diffusion susceptibility test with azithromycin. Journal of Antimicrobial Chemotherapy 22, 637–41.
3. Barry, A. L., Jones, R. N. & Thornsberry, C. (1988). In vitro activities of azithromycin (CP-62, 993), clarithromycin, erythromycin, roxithromycin and clindamycin. Antimicrobial Agents and Chemotherapy 32, 752–4.
4. Bergogne-Bérézin, E. (1987). Tissue distribution of roxithromycin. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 113–20.
5. Bergogne-Bérézin, E. (1988). Spiramycin concentrations in the human respiratory tract; a review. Journal of Antimicrobial Chemotherapy 22, Suppl. B, 117–22.
6. Bright, G. M. Nagel, A. A., Bordner, J., Desai, K. A., Dibring, J. N., Nowakowska, J. et al. (1988). Synthesis, in-vitro and in-vivo activity of novel 9-deoxo-9a-aza-9a homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. Journal of Antibiotics 41, 1029–47.
7. Chun, A. H. C. & Seitz, J. A. (1977). Pharmacokinetics and biological availability of erythromycin. Infection 5, Suppl. 1, 14–22.
8. Dette, G. A. (1979). Vergleich der Gewebegagigkeit von Erythromycin. Infection 7, 129–45.
9. Dette, G. A., Knothe, M. & Herrmann, G. (1982). Erythromycin binding to human serum. Biochemical Pharmacology 31, 1081–7.
10. Dette, G. A. & Knothe, M. (1986). The binding protein of erythromycin in human serum. Biochemical Pharmacology 35, 959–66.
11. Dunkin, K. T., Jones, S. & Howard, A. J. (1988). The in-vitro activity of CP-62, 993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci. Journal of Antimicrobial Chemotherapy 21, 405–11.
12. Fiese, E. F. & Steffen, S. H. (1990). Comparison of the acid stability of azithromycin and erythromycin A. Journal of Antimicrobial Chemotherapy, 25, Suppl. A, 39–47.
13. Gibaldi, M. & Perrier, D. (1982). Pharmacokinetics, 2nd edn, pp. 445–449. Marcel Dekker Inc., New York.
14. Girard, A. E., Girard, D., English, A. E., Gootz, T. D., Cimochowski, C. K., Faiella, J. A., et al. (1987). Pharmacokinetic and in-vivo studies with azithromycin (CP-62, 993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 31, 1948–54.
15. Girard, A. E., Girard, D. & Retsema, J. A., (1990). Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localised infection. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 61–71.
16. Kavi, J., Webberley, J. M., Andrews, J. M. & Wise, R. (1988). A comparison of the pharmacokinetics and tissue penetration of spiramydn and erythromycin. Journal of Antimicrobial Chemotherapy 22, Suppl. B, 105–10.
17. Lee, C.-C., Anderson, R. C. & Chen, K. K. (1956). Distribution and excretion of radioactivity in rats receiving N-methyl-Cl4-erythromycin. Journal of Pharmacology and Experimental Therapy 117, 265–73.
18. Puri, S. K. & lassman, H. B. (1987). Roxithromycin: A pharmacokinetic review of a macrolide. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 89–100.
19. Retsema, J., Girard, A., Shelkley, W., Manousos, M., Anderson, M., Bright, M. et al. (1987). Spectrum and mode of action of azithromycin (CP-62, 993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrobial Agents and Chemotherapy 31, 1939–47.
20. Retsema, J. A., Girard, A. E., Girard, D. & Milisen, W. P. (1990). Relationship of high tissue concentrations of azithromycin to bacteriddal activity and efficacy in vivo. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 83–9.
21. Ryan, R. W., Kwasnik, I. & Tilton, R. C. (1986). In-vitro activity of the macrolide CP-62, 993/XZ-450 against selected organisms. In Program and Abstracts of the Twenty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1986. Abstract 932, p. 267. American Society for Microbiology, Washington, DC.
22. Shepard, R. M. (1987). High pressure liquid chromatography (HPLQ assay for azithromycin (CP-62, 993/XZ-450) in serum and tissues. In Program and Abstracts of the Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, 1987. Abstract 238, p. 138. American Society for Microbiology, Washington, DC.
23. Shepard, R. M. & Falkner, F. C. (1990). Pharmacokinetics of azithromycin in rats and dogs. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 49–60.
24. Shepard, R. M., Weidler, D. J., Garg, D. C., Madsen, P. O., Cox, C. E., Chan, K. H., et al. (1987). Human pharmacokinetics of azithromycin (CP-62, 993/XZ450), a new macrolide with an extended half-life and high tissue penetration. In Program and Abstracts of the Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, 1987. Abstract 239, p. 138. American Society for Microbiology, Washington, DC.
25. Slaney, L., Chubb, H., Ronald, A. & Brunham, R. (1990). In-vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi and Chlamydia trachomatis. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 1–5.
26. Steingrimsson, O., Olafsson, J. H., Thorarinsson, H., Ryan, R. W., Johnson, R. B. & Tilton, R. C. (1990). Azithromycin in the treatment of sexually transmitted disease. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 109–14.
27. Walsh, M., Kappus, E. W. & Quinn, T. C. (1987). In-vitro evaluation of CP-62, 993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy 31, 811–2.
28. Washington, J. A. & Wilson, W. R. (1985). Erythromycin: A microbial and clinical perspective after 30 years of clinical use. Mayo Clinic Proceedings 60, 189–203, 271–8.
29. Wilson, J. T. & van Boxtel, C. J. (1978). Pharmacokinetics of erythromycin in man. Antibiotics and Chemotherapy 25, 181–203.
30. Wise, R., Kirkpatrick, B., Ashby, J. & Andrews, J. M. (1987). Pharmacokinetics and tissue penetration of roxithromycin after multiple dosing. Antimicrobial Agents and Chemotherapy 31, 1051–3.
31. Zini, R., Foumet, M. P., Barre, J., Tremblay, D. & Tillement, J.-P. (1988). In-vitro study of roxithromycin binding to serum proteins and erythrocytes in man. British Journal of Clinical Practice 42, Suppl. 55, 54.